DOI: https://doi.org/10.22263/2312-4156.2019.3.16
Budritsky A.M.1, Ivkin D.Y.2, Okovitiy S.V.2, Ivkina A.S.2, Sukhanov D.S.2, Dziuba A.S.3
Drawing up reviews on preclinical trials of medicines on the example of bismuth subsalicylate
1Vitebsk State Order of Peoples’ Friendship Medical University, Vitebsk, Republic of Belarus
2St. Petersburg State Chemical and Pharmaceutical University, Saint-Petersburg, Russian Federation
3JSC «PharmProject», Saint-Petersburg, Russian Federation
Vestnik VGMU. 2019;18(3):16-31.
Abstract.
The analysis of physical and chemical properties, toxicological profile and preclinical efficiency of bismuth subsalicylate substance (according to PubMed base) on different types of animals in the conditions of the digestive tract pathology has been made in the review. The antidiarrheal activity of this combination as well as its antiedematous and antiemetic properties have been determined. The adsorbing properties of the substance on administration of endotoxins of causative agents of bacterial intestinal infections and exotoxin of cholera vibrion have been considered and also its influence on the reproduction of rotaviruses and the course of noninfectious diarrheas. Besides, the gastroprotective activity of bismuth subsalicylate on the influence of gastric factors of aggression has been shown which was complemented by its expressed antisecretory and anti-inflammatory activity against the background of inflammatory diseases of the intestines. On consideration of pharmacokinetics we have determined low absorption of active combination in the digestive tract, similar to that while administering bismuth dicitrate tripotassium which may prevent bismuth-induced neurotoxicity development. The preclinical efficiency of the substance in complex schemes of H. pylori eradication and also on noninfectious oxidative influence on the gastric mucosa has been established. The consideration of the received results is useful to researchers for planning further preclinical trials of bismuth preparations with regard to test systems, models, duration of an experiment and the choice of doses as well as the possibility of planning clinical tests.
Key words: review, preclinical trials, medicinal agent, bismuth subsalicylate.
References
1. Sun H, red. Biological Chemistry of Arsenic, Antimony and Bismuth. Singapore: John Wiley & Sons Ltd; 2011. 400 р.
2. Ahmad S, Isab AA, Ali S, Al-Arfaj AR. Perspectives in bioinorganic chemistry of some metal based therapeutic agents. Polyhedron. 2006;25(7):1633-45.
3. Briand GG, Burford N. Bismuth compounds and preparations with biological or medicinal relevance. Chem Rev. 1999 Sep;99(9):2601-58.
4. Sun HZ, Li HY, Sadler PJ. The biological and medicinal chemistry of bismuth. Chem Ber Rec. 1997 Jun;130(6):669-81.
5. Sun H, Zhang L, Szeto K-Y. Bismuth in medicine. In: Sigel A, Sigel H, ed. Metal Ions in Biological Systems. Vol 41: Metal Ions and Their Complexes in Medication. New York: Marcel Dekker; 2004. Chapt 11. P. 333-78.
6. Li H, Sun H. Recent advances in bioinorganic chemistry of bismuth. Curr Opin Chem Biol. 2012 Apr;16(1-2):74-83. doi: http://dx.doi.org/10.1016/j.cbpa.2012.01.006
7. Ge RG, Sun HZ. Bioinorganic chemistry of bismuth and antimony: target sites of metallodrugs. Acc Chem Res. 2007 Apr;40(4):267-74. doi: http://dx.doi.org/10.1021/ar600001b
8. Okovityy SV, Ivkin DYu. Bismuth preparations – pharmacological foundations of clinical effect. Lechashchii Vrach. 2015;(10):67-73. (In Russ.)
9. Mohan R. Green bismuth. Nat Chem. 2010 Apr;2(4):336. doi: http://dx.doi.org/10.1038/nchem.609
10. Suzuki H. Introduction. In: Suzuki H, Matano Y. ed. Organobismuth Chemistry. Amsterdam: Elsevier; 2001. P. 1-20.
11. Suzuki H, Ikegami T, Matano Y. Bismuth in organic transformations. Synthesis. 1997;(3):249-67. doi: http://dx.doi.org/0.1055/s-1997-1194
12. Barton DHR, Finet JP. Bismuth(V) reagents in organic synthesis. Pure Appl Chem. 1987;59(8):937-46. doi: http://dx.doi.org/10.1351/pac198759080937
13. Le Roux C, Dubac J. Bismuth(III) chloride and triflate: novel catalysts for acylation and sulfonylation reactions. Survey and mechanistic aspects. Synlett. 2002;2:181-200. doi: http://dx.doi.org/10.1055/s-2002-19743
14. Gaspard-Iloughmane H, Le Roux C. Bismuth(III) triflate in organic synthesis. Eur J Org Chem. 2004;12:2517-32. doi: http://dx.doi.org/10.1002/ejoc.200300754
15. Leonard NM, Wieland LC, Mohan RS. Applications of bismuth(III) compounds in organic synthesis. Chem Soc Rev. 2011 Sep;40(9):4649-707. doi: http://dx.doi.org/10.1039/c0cs00206b
16. Salvador JA, Figueiredo SA, Pinto RM, Silvestre SM. Bismuth compounds in medicinal chemistry. Future Med Chem. 2012 Jul;4(11):1495-523. doi: http://dx.doi.org/10.4155/fmc.12.95
17. Yang N, Sun H. Biological chemistry of antimony and bismuth. In: Sun H, ed. Biological Chemistry of Arsenic, Antimony and Bismuth. Singapore: John Wiley & Sons Ltd; 2011.
18. Silvestru C, Breunig HJ, Althaus H. Structural chemistry of bismuth compounds. I. Organobismuth derivatives. Chem Rev. 1999 Nov;99(11):3277-328.
19. Mendis AHW, Marshall BJ. Helicobacter pylori and bismuth. In: Sun H, ed. Biological Chemistry of Arsenic, Antimony and Bismuth. Singapore: John Wiley & Sons Ltd; 2011.
20. Kolmer JA. Tryparsamide and bismuth subsalicylate in the treatment of experimental syphilis of rabbits; synergistic or additive activity. Arch Derm Syphilol. 1950 Feb;61(2):271-5.
21. Kolmer JA. Penicillin in the treatment of experimental syphilis of rabbits. VII. Penicillin «S-R» and procaine penicillin G in peanut oil with aluminum monostearate, alone and in combination with oxophenarsine hydrochloride (mapharsen) or bismuth subsalicylate. AMA Arch Derm Syphilol. 1951 Aug;64(2):169-76.
22. Goldenberg MM, Honkomp LJ, Castellion AW. The antidiarrheal action of bismuth subsalicylate in the mouse and the rat. Am J Dig Dis. 1975 Oct;20(10):955-60.
23. Goldenberg MM, Honkomp LJ, Davis CS. Antinauseant and antiemetic properties of bismuth subsalicylate in dogs and humans. J Pharm Sci. 1976 Sep;65(9):1398-400.
24. Ericsson CD, Evans DG, DuPont HL, Evans DJ Jr, Pickering LK. Bismuth subsalicylate inhibits activity of crude toxins of Escherichia coli and Vibrio cholera. J Infect Dis. 1977 Nov;136(5):693-6. doi: http://dx.doi.org/10.1093/infdis/136.5.693
25. Goldenberg MM, Honkomp LJ, Castellion AW. Prevention by bismuth subsalicylate of gastric mucosal lesions in response to noxious stimuli in rats. Pharmacol Res Commun. 1978 Jan;10(1):13-20.
26. Gyles CL, Zigler M. The effect of adsorbant and anti-inflammatory drugs on secretion in ligated segments of pig intestine infected with Escherichia coli. Can J Comp Med. 1978 Jul;42(3):260-8.
27. Scevola D, Barbarini G, Marone P, Azzini M, Filice C, Bernardi R. Anti-endotoxin therapy in liver diseases. G Ital Chemioter. 1979 Jan-Dec;26(1-2):241-56.
28. Goldenberg MM, Brooks RR, Boise KL. Comparative evaluation of gastrointestinal blood loss in the feces of rats following Pepto-Bismol liquid and aspirin administration. Life Sci. 1980 Apr;26(16):1335-42.
29. Ward RL, Sander DS, Knowlton DR. In vitro activities of bismuth salts against rotaviruses and other enteric viruses. Antimicrob Agents Chemother. 1985 Mar;27(3):306-8.
30. Slocombe RF, Evans MG, Derksen FJ. Histopathologic findings and energy dispersive X-ray spectroscopic analysis of experimentally induced foreign-body pneumonias in rats. Vet Pathol. 1989 Nov;26(6):479-87. doi: http://dx.doi.org/10.1177/030098588902600604
31. Tay HP, Chaparala RC, Harmon JW, Huesken J, Saini N, Hakki FZ, et al. Bismuth subsalicylate reduces peptic injury of the oesophagus in rabbits. Gut. 1990 Jan;31(1):11-6. doi: http://dx.doi.org/10.1136/gut.31.1.11
32. Ericsson CD, Tannenbaum C, Charles TT. Antisecretory and antiinflammatory properties of bismuth subsalicylate. Rev Infect Dis. 1990 Jan-Feb;12 Suppl 1:S16-20.
33. Chang TW, Dong MY, Gorbach SL. Effect of bismuth subsalicylate on Clostridium difficile colitis in hamsters. Rev Infect Dis. 1990 Jan-Feb;12 Suppl 1:S57-8.
34. Bierer DW. Bismuth subsalicylate: history, chemistry, and safety. Rev Infect Dis. 1990 Jan-Feb;12 Suppl 1:S3-8.
35. Hänninen ML. Bismuth subsalicylate in the prevention of colonization of infant mice with Campylobacter jejuni. Epidemiol Infect. 1990 Jun;104(3):397-404. doi: http://dx.doi.org/10.1017/s0950268800047415
36. Otto G, Fox JG, Wu PY, Taylor NS. Eradication of Helicobacter mustelae from the ferret stomach: an animal model of Helicobacter (Campylobacter) pylori chemotherapy. Antimicrob Agents Chemother. 1990 Jun;34(6):1232-6. doi: http://dx.doi.org/10.1128/aac.34.6.1232
37. Roussel AJJr, Brumbaugh GW. Treatment of diarrhea of neonatal calves. Vet Clin North Am Food Anim Pract. 1991 Nov;7(3):713-28.
38. Copeman M, Matuz J, Leonard AJ, Pearson JP, Dettmar PW, Allen A. The gastroduodenal mucus barrier and its role in protection against luminal pepsins: the effect of 16,16 dimethyl prostaglandin E2, carbopol-polyacrylate, sucralfate and bismuth subsalicylate. J Gastroenterol Hepatol. 1994;9 Suppl 1:S55-9.
39. Horowitz NS, Staats HF, Palker TJ. Effect of bismuth salts on systemic and mucosal immune responses to orally administered cholera toxin. Immunopharmacology. 1995 Nov;31(1):31-41.
40. Batchelder M, Fox JG, Hayward A, Yan L, Shames B, Murphy JC, et al. Natural and experimental Helicobacter mustelae reinfection following successful antimicrobial eradication in ferrets. Helicobacter. 1996 Mar;1(1):34-42.
41. Czinn SJ, Bierman JC, Diters RW, Blanchard TG, Leunk RD. Characterization and therapy for experimental infection by Helicobacter mustelae in ferrets. Helicobacter. 1996 Mar;1(1):43-51.
42. Clark CK, Merritt AM, Burrow JA, Steible CK. Effect of aluminum hydroxide/magnesium hydroxide antacid and bismuth subsalicylate on gastric pH in horses. J Am Vet Med Assoc. 1996 May 15;208(10):1687-91.
43. Greenfield RA, Mosier DA, Crawford DL, Abrams VL, Kuhls TL. Bismuth subsalicylate prophylaxis of Cryptosporidium parvum infection in immunodeficient mice. J Eukaryot Microbiol. 1996 Sep-Oct;43(5):69S.
44. Rao N, Brown PW, Yerino P, Chang J, Hwang KK. Comparative absorption of bismuth in Sprague-Dawley rats following oral administration of preparations containing bismuth sucrose octasulfate, bismuth subsalicylate, and bismuth subcitrate. Biopharm Drug Dispos. 1997 Jan;18(1):1-8.
45. Tanaka S, Guth PH, Carryl OR, Kaunitz JD. Cytoprotective effect of bismuth subsalicylate in indomethacin-treated rats is associated with enhanced mucus bismuth concentration. Aliment Pharmacol Ther. 1997 Jun;11(3):605-12.
46. Bagchi D, Carryl OR, Tran MX, Bagchi M, Vuchetich PJ, Krohn RL, et al. Protection against chemically-induced oxidative gastrointestinal tissue injury in rats by bismuth salts. Dig Dis Sci. 1997 Sep;42(9):1890-900.
47. Wack RF, Eaton KA, Kramer LW. Treatment of gastritis in cheetahs (Acinonyx jubatus). J Zoo Wildl Med. 1997 Sep;28(3):260-6.
48. Dubois A, Berg DE, Fiala N, Heman-Ackah LM, Perez-Perez GI, Blaser MJ. Cure of Helicobacter pylori infection by omeprazole-clarithromycin-based therapy in non-human primates. J Gastroenterol. 1998 Feb;33(1):18-22.
49. Bagchi D, Carryl OR, Tran MX, Krohn RL, Bagchi DJ, Garg A, et al. Stress, diet and alcohol-induced oxidative gastrointestinal mucosal injury in rats and protection by bismuth subsalicylate. J Appl Toxicol. 1998 Jan-Feb;18(1):3-13.
50. Krakowka S, Eaton KA, Leunk RD. Antimicrobial therapies for Helicobacter pylori infection in gnotobiotic piglets. Antimicrob Agents Chemother. 1998 Jul;42(7):1549-54.
51. Lichtenberger LM, Romero JJ, Carryl OR, Illich PA, Walters ET. Effect of pepper and bismuth subsalicylate on gastric pain and surface hydrophobicity in the rat. Aliment Pharmacol Ther. 1998 May;12(5):483-90.
52. Bagchi D, Carryl OR, Tran MX, Bagchi M, Garg A, Milnes MM, et al. Acute and chronic stress-induced oxidative gastrointestinal mucosal injury in rats and protection by bismuth subsalicylate. Mol Cell Biochem. 1999 Jun;196(1-2):109-16.
53. Willard MD, Bouley D. Cryptosporidiosis, coccidiosis, and total colonic mucosal collapse in an immunosuppressed puppy. J Am Anim Hosp Assoc. 1999 Sep-Oct;35(5):405-9. doi: http://dx.doi.org/10.5326/15473317-35-5-405
54. Peterson TC, Cleary CE, Shaw AM, Malatjalian DA, Veldhuyzen van Zanten SJ. Therapeutic role for bismuth compounds in TNBS-induced colitis in the rat. Dig Dis Sci. 2000 Mar;45(3):466-73.
55. Furne JK, Suarez FL, Ewing SL, Springfield J, Levitt MD. Binding of hydrogen sulfide by bismuth does not prevent dextran sulfate-induced colitis in rats. Dig Dis Sci. 2000 Jul;45(7):1439-43.
56. Suarez FL,Furne J, Stiehm J, Garten C, Levitt MD. Site of bismuth absorption from bismuth subsalicylate: implications for treatment of colonic conditions. Dig Dis Sci. 2000 Jul;45(7):1444-6.
57. Pamphlett R, Stoltenberg M, Rungby J, Danscher G. Uptake of bismuth in motor neurons of mice after single oral doses of bismuth compounds. Neurotoxicol Teratol. 2000 Jul-Aug;22(4):559-63.
58. Leib MS, Duncan RB, Ward DL. Triple antimicrobial therapy and acid suppression in dogs with chronic vomiting and gastric Helicobacter spp. J Vet Intern Med. 2007 Nov-Dec;21(6):1185-92. doi: http://dx.doi.org/10.1892/06-135.1
59. Atkins A, Wellehan JF Jr, Childress AL, Archer LL, Fraser WA, Citino SB. Characterization of an outbreak of astroviral diarrhea in a group of cheetahs (Acinonyx jubatus). Vet Microbiol. 2009 Apr 14;136(1-2):160-5. doi: http://dx.doi.org/10.1016/j.vetmic.2008.10.035
60. Mongan J, Rathnayake S, Fu Y, Gao DW, Yeh BM. Extravasated contrast material in penetrating abdominopelvic trauma: dual-contrast dual-energy CT for improved diagnosis-preliminary results in an animal model. Radiology. 2013 Sep;268(3):738-42. doi: http://dx.doi.org/10.1148/radiol.13121267
61. Johnson AL, Blaine ET, Lewis AD. Renal pigmentation due to chronic bismuth administration in a rhesus macaque (Macaca mulatta). Vet Pathol. 2015 May;52(3):576-9. doi: http://dx.doi.org/10.1177/0300985814541707
62. Pitz AM, Park GW, Lee D, Boissy YL, Vinjé J. Antimicrobial activity of bismuth subsalicylate on Clostridium difficile, Escherichia coli O157:H7, norovirus, and other common enteric pathogens. Gut Microbes. 2015;6(2):93-100. doi: http://dx.doi.org/10.1080/19490976.2015.1008336
63. Ruiz-Moreno M, Binversie E, Fessenden SW, Stern MD. Mitigation of in vitro hydrogen sulfide production using bismuth subsalicylate with and without monensin in beef feedlot diets. J Anim Sci. 2015 Nov;93(11):5346-54. doi: http://dx.doi.org/10.2527/jas.2015-9392
Information about authors:
Budritsky A.M. – Candidate of Medical Sciences, associate professor, head of the Chair of Phthisiopulmonology, Vitebsk State Order of Peoples’ Friendship Medical University;
Ivkin D.Y. – Candidate of Biological Sciences, associate professor of the Chair of Pharmacology & Clinical Pharmacology, head of the Center of Experimental Pharmacology, Saint-Petersburg State Chemical and Pharmaceutical University;
Okovitiy S.V. – Doctor of Medical Sciences, professor, head of the Chair of Pharmacology & Clinical Pharmacology, Saint-Petersburg State Chemical and Pharmaceutical University;
Ivkina A.S. – research officer of the Center of Experimental Pharmacology, Saint-Petersburg State Chemical and Pharmaceutical University;
Sukhanov D.S. – Doctor of Medical Sciences, professor of the Chair of Pharmacology & Clinical Pharmacology, Saint-Petersburg State Chemical and Pharmaceutical University;
Dziuba A.S. – Candidate of Pharmaceutical Sciences, head of R & D Department of JSC «PharmProject».
Correspondence address: Republic of Belarus, 210009, Vitebsk, 27 Frunze ave., Vitebsk State Order of Peoples’ Friendship Medical University, Chair of Phthisiopulmonology E-mail: Этот адрес электронной почты защищён от спам-ботов. У вас должен быть включен JavaScript для просмотра. – Alexander M. Budritsky.
